Besides, ccRCC neutrophil could resist anticancer immune therapies of ipilimumab and pembrolizumab for their low/no expressions of CTLA-4, PD-1, and PD-L1. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.